RAINBOW: A GLOBAL, PHASE 3, DOUBLE-BLIND STUDY OF RAMUCIRUMAB (RAM) PLUS PACLITAXEL (PTX) VERSUS PLACEBO (PL) plus PTX IN THE TREATMENT OF ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA FOLLOWING DISEASE PROGRESSION ON FIRST-LINE PLATINUM- AND FLUOROPYRIMIDINE-CONTAINING COMBINATION THERAPY: A SUBGROUP ANALYSIS OF WESTERN POPULATION

被引：0

作者：

Wilke, Hansjochen ^{[1
]}

Clingan, Philip ^{[2
]}

Ananda, Sumi ^{[3
]}

Kurteva, Galina ^{[4
]}

Suuroja, Tiit ^{[5
]}

Folprecht, Gunnar ^{[6
]}

Beny, Alexander ^{[7
]}

Pastorelli, Davide ^{[8
]}

Cesas, Alvydas ^{[9
]}

Nowecki, Zbigniew ^{[10
]}

Toganel, Cornelia ^{[11
]}

Bodoky, Gyoergy ^{[12
]}

Lipatov, Oleg ^{[13
]}

Miron, Maria Limon ^{[14
]}

Cunningham, David ^{[15
]}

Cummins, Sebastian ^{[16
]}

Wainberg, Zev ^{[17
]}

Ko, Andrew ^{[18
]}

Emig, Michael ^{[19
]}

Chandrawansa, Kumari ^{[20
]}

van Cutsem, Eric ^{[21
]}

机构：

[1] Kliniken Essen Mitte, Essen, Germany

[2] Southern Med Day Care Ctr, Wollongong, NSW, Australia

[3] Western Hlth, Melbourne, Vic, Australia

[4] Specialised Hosp Act Treatment Oncol, Sofia, Bulgaria

[5] North Estonia Med Ctr, Tallinn, Estonia

[6] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[7] Rambam Hlth Care Campus, Haifa, Israel

[8] Ist Oncol Veneto IRCCS, Padua, Italy

[9] Klaipeda Univ Hosp, Klaipeda, Lithuania

[10] Ctr Onkol Inst M Sklodowskiej Curie, Warsaw, Poland

[11] Spitalul Clin Judetean Mures, Targu Mures, Romania

[12] St Laszlo Hosp, Dept Oncol, Budapest, Hungary

[13] Republican Clin Oncol Dispensary, Ufa, Russia

[14] HUV Rocio, Seville, Spain

[15] Royal Marsden Hosp, London SW3 6JJ, England

[16] Royal Surrey Cty Hosp, Guildford, Surrey, England

[17] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[18] Univ Calif San Francisco, San Francisco, CA 94143 USA

[19] Eli Lilly & Co, Homburg, Germany

[20] Eli Lilly & Co, Indianapolis, IN 46285 USA

[21] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 10卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

362

引用

页码：171 / 171

页数：1

共 45 条

[31] A phase 3 randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma. [J].

Bendell, Johanna C. ;

Starodub, Alexander ;

Wainberg, Zev A. ;

Wu, Meihua ;

Werner, Douglas ;

Maltzman, Julia D. ;

Shah, Manish A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[32] A phase 3 randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma. [J].

Bendel, Johanna C. ;

Starodub, Alexander ;

Huang, Xi ;

Maltzman, Julia D. ;

Wainberg, Zev A. ;

Shah, Manish A. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[33] A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780). [J].

Grothey, Axel ;

Tabernero, Josep ;

Rougier, Philippe ;

Ballal, Shaila ;

Crane, Heidi ;

Rutstein, Mark D. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[34] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].

Garon, Edward B. ;

Ciuleanu, Tudor-Eliade ;

Arrieta, Oscar ;

Prabhash, Kumar ;

Syrigos, Konstantinos N. ;

Goksel, Tuncay ;

Park, Keunchil ;

Gorbunova, Vera ;

Dario Kowalyszyn, Ruben ;

Pikiel, Joanna ;

Czyzewicz, Grzegorz ;

Orlov, Sergey V. ;

Lewanski, Conrad R. ;

Thomas, Michael ;

Bidoli, Paolo ;

Dakhil, Shaker ;

Gans, Steven ;

Kim, Joo-Hang ;

Grigorescu, Alexandru ;

Karaseva, Nina ;

Reck, Martin ;

Cappuzzo, Federico ;

Alexandris, Ekaterine ;

Sashegyi, Andreas ;

Yurasov, Sergey ;

Perol, Maurice .

LANCET, 2014, 384 (9944) :665-673

[35] A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma. [J].

Bendell, Johanna C. ;

Starodub, Alexander ;

Huang, Xi ;

Maltzman, Julia D. ;

Wainberg, Zev A. ;

Shah, Manish A. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

[36] RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp) [J].

Tabernero, Josep ;

Cohn, Allen Lee ;

Obermannova, Radka ;

Bodoky, Gyorgy ;

Garcia-Carbonero, Rocio ;

Ciuleanu, Tudor-Eliade ;

Portnoy, David Craig ;

Van Cutsem, Eric ;

Grothey, Axel ;

Prausova, Jana ;

Garcia-Alfonso, Pilar ;

Yamazaki, Kentaro ;

Clingan, Philip R. ;

Zagonel, Vittorina ;

Kim, Tae Won ;

Simms, Lorinda ;

Chang, Shao-Chun ;

Nasroulah, Federico ;

Yoshino, Takayuki .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

[37] Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study [J].

Cunningham, David ;

Tebbutt, Niall C. ;

Davidenko, Irina ;

Murad, Andre M. ;

Al-Batran, Salah-Eddin ;

Ilson, David H. ;

Tjulandin, Sergei ;

Gotovkin, Evgeny ;

Karaszewska, Boguslawa ;

Bondarenko, Igor ;

Tejani, Mohamedtaki Abdulaziz ;

Udrea, Anghel Adrian ;

Tehfe, Mustapha Ali ;

Baker, Nigel ;

Oliner, Kelly Smith ;

Zhang, Yilong ;

Hoang, Tien ;

Sidhu, Roger ;

Catenacci, Daniel Virgil Thomas .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[38] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) [J].

Yoon, H. ;

Kato, K. ;

Raymond, E. ;

Hubner, R. ;

Shu, Y. ;

Pan, Y. ;

Jiang, Y. ;

Zhang, J. ;

Park, S. ;

Kojima, T. ;

Lin, C. ;

Gotovkin, E. ;

Wyrwicz, L. ;

Ishihara, R. ;

Li, L. ;

Tao, A. ;

Shi, J. ;

Wang, L. ;

Xu, J. .

ANNALS OF ONCOLOGY, 2022, 33 :S375-S375

[39] Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status [J].

Sobrero, A. ;

Latini, L. ;

Barone, C. ;

Capuzzo, F. ;

Banzi, M. ;

Nasroulah, F. ;

Sims, L. ;

Tabernero, J. .

ANNALS OF ONCOLOGY, 2015, 26 :37-37

[40] Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study [J].

Shitara, Kohei ;

Gumus, Mahmut ;

Pietrantonio, Filippo ;

Lonardi, Sara ;

De La Fouchardiere, Christelle ;

Coutzac, Clelia ;

Dekervel, Jeroen ;

Hochhauser, Daniel ;

Shen, Lin ;

Mansoor, Wasat ;

Liu, Bo ;

Fornaro, Lorenzo ;

Ryu, Min-Hee ;

Lee, Jeeyun ;

Souza, Fabricio ;

Jukofsky, Lori ;

Zhao, Yumin ;

Kamio, Takahiro ;

Zaanan, Aziz ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (17_SUPPL) :LBA4002-LBA4002

← 1 2 3 4 5 →